ArticleScience advances2025
Oropouche virus efficiently replicates and is immunostimulatory in vivo in nonhuman primate species.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.Virulence · 2026Review
- Oropouche virus infection: clinical spectrum, geographic expansion, and emerging maternal-fetal implications.Infection · 2026Review
- Addressing Key Issues in Developing Safe and Effective Oropouche Virus Vaccines.Journal of medical virology · 2026Article
- An engineered anti-Oropouche virus human-murine chimeric immunoglobulin M is a viable substitute for positive human serum controls in diagnostic serology assays.PLoS neglected tropical diseases · 2026Article
- Oropouche Virus: Comparative Study of Two Strains Reveals Distinct Innate Immunity Modulation.Viruses · 2026Article
- Review
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- Article
- Preclinical Models of Oropouche Virus Infection and Disease.Pathogens (Basel, Switzerland) · 2025Review
- Charting the Proteins of Oropouche Virus.Viruses · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An Oropouche virus (OROV) outbreak occurred in South America in 2024. The pathogenic potential and host immunological response of this emerging virus are largely unknown, as animal models have been poorly explored. We infected nonhuman primate (NHP) species with OROV and followed viral replication dynamics and subsequent innate and adaptive immunological responses. OROV efficiently replicated in pigtail macaques, rhesus macaques, and vervet African green monkeys. OROV also replicated in sabeus African green monkey, albeit at lower levels than other hosts. OROV RNA was detected in plasma and nasal swabs and infection-induced high levels of innate inflammation, type I interferon gene signatures, immunoglobulin M-positive B cell expansion, high titers of neutralizing antibodies, and detectable frequencies of OROV-specific T cells. Prior infection was protective against reinfection up to 524 days post-initial infection, demonstrating possible protective immunity induction against OROV infection. These data suggest that multiple NHP species are appropriate models for OROV infection and the development of therapeutics and vaccinations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.